Your browser doesn't support javascript.
loading
Liver fat content measured by magnetic resonance spectroscopy at 3.0 tesla independently correlates with plasminogen activator inhibitor-1 and body mass index in type 2 diabetic subjects.
Ishii, Mototsugu; Yoshioka, Yoshichika; Ishida, Wataru; Kaneko, Yoshihito; Fujiwara, Fumikado; Taneichi, Haruhito; Miura, Masanori; Toshihiro, Makiko; Takebe, Noriko; Iwai, Masakatsu; Suzuki, Kazuyuki; Satoh, Jo.
Afiliação
  • Ishii M; Department of Diabetes and Metabolism, Iwate Medical University, Morioka, Japan. hozisik@inonu.edu.tr
Tohoku J Exp Med ; 206(1): 23-30, 2005 May.
Article em En | MEDLINE | ID: mdl-15802872
ABSTRACT
We measured liver fat content by 3-Tesla magnetic resonance spectroscopy (MRS) in 34 non- to mild obese Japanese subjects with type 2 diabetes, who were not complicated with any liver diseases including clinical fatty liver (liver/spleen ratio of computed tomography [CT] < 0.9) and were not being treated with oral hypoglycemic agents, insulin, or lipid-lowering agents, and analyzed the relationship between liver fat content and body composition and plasma metabolite. The liver fat content is significantly correlated with variables relating to obesity (body mass index [BMI], body weight, fat mass, waist to hip ratio, visceral fat area, subcutaneous fat area, and serum triglyceride), insulin resistance (fasting plasma insulin and homeostasis model assessment of insulin resistance [HOMA-IR]), adipocytokines (serum plasminogen activator inhibitor-1 [PAI-1] and leptin), and serum cholinesterase, but not CT liver/spleen ratio, which is correlated only with fasting plasma glucose, BMI, and HOMA-IR. Multiple regression analysis revealed that the liver fat content is independently associated with serum PAI-1 level (p < 0.001) and BMI (p < 0.05), but not visceral fat area. MRS is a more sensitive method for quantifying liver fat content than CT in type 2 diabetic subjects with non- to mild obesity and without clinical fatty liver.
Assuntos
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Índice de Massa Corporal / Inibidor 1 de Ativador de Plasminogênio / Diabetes Mellitus Tipo 2 / Metabolismo dos Lipídeos / Fígado Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Female / Humans / Male Idioma: En Revista: Tohoku J Exp Med Ano de publicação: 2005 Tipo de documento: Article
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Índice de Massa Corporal / Inibidor 1 de Ativador de Plasminogênio / Diabetes Mellitus Tipo 2 / Metabolismo dos Lipídeos / Fígado Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Female / Humans / Male Idioma: En Revista: Tohoku J Exp Med Ano de publicação: 2005 Tipo de documento: Article